ClinicalTrials.Veeva

Menu

Role of Children in Transmission of COVID-19 to Immunocompromised Patients

Jonsson Comprehensive Cancer Center logo

Jonsson Comprehensive Cancer Center

Status

Terminated

Conditions

Immunosuppression

Study type

Observational

Funder types

Other

Identifiers

NCT04407546
NCI-2020-03669 (Registry Identifier)
20-000517

Details and patient eligibility

About

This is a study of immunosuppressed individuals living in households with and without children to assess the role of household contact with children in the transmission of SARSCoV-2 to immunocompromised individuals. Through careful collection of epidemiological data in combination with biological specimens, risk factors for SARS-CoV-2 in immunocompromised individuals will be identified. During the initial visits, informed consent will be obtained and consented participants will complete an initial questionnaire and provide biological specimens including nasal swabs, saliva and blood. Thereafter, participants will complete at-home saliva collections and questionnaires on a weekly basis for 6 months. If our research-use only SARS-CoV-2 test is positive, participants will be referred immediately for medical attention and will be followed every 3 days with nasal swabs and saliva samples and weekly blood specimens and optional rectal swabs or fresh stool collection. Additionally, participants will be contacted by telephone at 1 year for follow-up.

Full description

This is a prospective, longitudinal cohort study of immunosuppressed patients living in households with and without children to assess the role of household contact with children in the transmission of SARS-CoV-2 to immunocompromised patients. This study will be enrolling both pediatric and adult patients who are immunosuppressed, as well as their household members who agree to participate. Through careful collection of epidemiological data in combination with biological specimens, risk factors for SARS- CoV-2 in immunocompromised patients will be identified. During the initial study visit, informed consent will be obtained, the study questionnaire will be completed and the participant will provide biological specimens including nasal mid-turbinate swabs, saliva and blood. Thereafter, participants will complete at-home saliva collections and questionnaires on a weekly basis for 6 months. If our research-use only SARS-CoV-2 test is positive, participants will be referred immediately to University of California at Los Angeles(UCLA) Health for medical attention and will be followed every 3 days with nasal swabs and saliva samples, and weekly blood specimens and optional rectal swabs or fresh stool collection. Biological specimen and questionnaire follow-up will occur for 6 months for uninfected participants or until the of end of viral shedding and immunologic profiling for patients infected with SARS-CoV-2, whichever is longer. All participants will be followed at 6 months with the same baseline measurements and then participants will be contacted by telephone at 1 year.

The clinical data and biological specimens collected in this initial study will provide will inform and allow future studies of clinical outcomes, viral characteristics, and immune responses to SARS-CoV-2 infection.

Enrollment

109 patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Immunocompromised patient followed at UCLA Health
  • Immunocompromised patient >1 day old to <60 years of age
  • Patient with a diagnosis of breast, lung, or colorectal cancers, lymphoma, acute/chronic leukemia, multiple myeloma, or other solid tumors and are receiving chemotherapy
  • Patients who have received a hematopoietic stem cell transplantation within the last year
  • Patients who have received a solid organ transplantation within the last year

Exclusion criteria

  • Immunocompromised patients with positive SARS-CoV-2 test prior to study enrollment

Trial design

109 participants in 2 patient groups

Families with Children
Description:
Families containing an immunocompromised individual that have children in the family setting.
Famlies without children
Description:
Families containing an immunocompromised individual that do not have children in the family setting.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems